Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the
list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) …

Oligonucleotide-based therapies are a promising approach for treating a wide range of hard-
to-treat diseases, particularly genetic and rare diseases. These therapies involve the use of …

The lung is a complex organ with various cell types having distinct roles. Antisense
oligonucleotides (ASOs) have been studied in the lung, but it has been challenging to …

Long noncoding RNAs (lncRNAs) are important regulators of various cellular functions.
Recent studies have shown that a novel lncRNA termed Punisher is highly expressed in …

Fuchs' endothelial corneal dystrophy (FECD) is the most common repeat expansion
disorder. FECD impacts 4% of US population and is the leading indication for corneal …

Muscle atrophy is the loss of muscle mass and strength, and it occurs in many diseases,
such as cancer, AIDS (acquired immunodeficiency syndrome), congestive heart failure …

Long non-coding RNAs (lncRNAs) are key regulators of numerous intracellular processes
leading to tumorigenesis. They are frequently deregulated in cancer, functioning as …

Asthma is a complex chronic respiratory disease characterized by airway
hyperresponsiveness, inflammation, and obstruction. Many genes have been identified as …

We conducted a biophysical study to investigate the self-assembling and albumin-binding
propensities of a series of fatty acid-modified locked nucleic acid (LNA) antisense …

Therapeutic oligonucleotides require the addition of multiple chemical modifications to the
nucleosidic scaffold in order to improve their drug delivery efficiency, cell penetration …